ClinicalTrials.gg
CompletedNCT07220954Updated Oct 15, 2026

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

A Phase 1 interventional study of AZD6234 Formulation 1 and AZD6234 Formulation 2 (low concentration) in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Updated Oct 15, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing AZD6234 in Obesity — 2 open to participants now, 4 under way, 1 of them phase 3. AZD6234 · Obesity.

Enrollment
9th of 10
19 · median 85
Started
2025
with 4 others
Phase 1
5 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
10 of 10
AstraZeneca

Among the 10 studies testing AZD6234 in Obesity, this one is the 9th largest by enrollment, is one of 5 that started in 2025, is one of 5 in phase 1, and was the 8th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 10 studies testing AZD6234 in Obesity are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About AZD6234

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing AZD6234 in Obesity, or all of them as a file.
02

Study summary

This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234.

This study will take place at one site in Nottingham, United Kingdom, and will enrol 21 healthy men and women aged 18-55 years.

Read the detailed description

This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234.

This study will take place at one site in Nottingham, United Kingdom.

It plans to enrol 21 healthy men and women aged 18-55 years.

Each volunteer will take part in 4 treatment periods and receive different formulations of AZD6234, by injection under the skin into the abdomen (stomach). In each period they'll be given a single dose without food. They'll stay in the clinic for 6 nights on 4 occasions, attend up to 10 outpatient visits, and take up to 19 weeks to finish the study.

Blood and urine samples will be collected to: measure the amount of AZD6234 and its breakdown products, do safety tests and assess the effect of the test medicine on the immune system response.

03

Conditions studied

  • Healthy Participants

Keywords

  • Relative Bioavailability
  • Pharmacokinetics
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive
  • of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder
  • History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or gastrointestinal disorder including a history of pancreatitis or gall stones
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the planned first dosing day
  • Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
  • Any clinically significant abnormal findings in vital signs
  • Any clinically significant abnormalities on 12-lead
  • ≥6.5% (≥48 mmol/mol)
  • Evidence of renal impairment
  • Females who are pregnant or lactating.
  • Any participant who has received an amylin analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer)
  • Participants who report to have previously received AZD6234.
  • Use of any prescribed or non-prescribed medication
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Sequence ABCD

    Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment A in Period 1, Treatment B in Period 2, Treatment C in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3)

    Drug: AZD6234 Formulation 1 · Drug: AZD6234 Formulation 2 (low concentration) · Drug: AZD6234 Formulation 2 (high concentration) · Drug: AZD6234 Formulation 3

  • Experimental
    Sequence BCAD

    Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment B in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3)

    Drug: AZD6234 Formulation 1 · Drug: AZD6234 Formulation 2 (low concentration) · Drug: AZD6234 Formulation 2 (high concentration) · Drug: AZD6234 Formulation 3

  • Experimental
    Sequence CABD

    Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment C in Period 1, Treatment A in Period 2, Treatment B in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3)

    Drug: AZD6234 Formulation 1 · Drug: AZD6234 Formulation 2 (low concentration) · Drug: AZD6234 Formulation 2 (high concentration) · Drug: AZD6234 Formulation 3

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations

    Time frame: Plasma sample collection from pre- dose to 30 days post final dose

  2. Area under the concentration-time curve from time 0 to the time of the last measurable concentration (AUC0-t)

    Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations

    Time frame: Plasma sample collection from pre- dose to 30 days post final dose

  3. Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)

    Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations

    Time frame: Plasma sample collection from pre- dose to 30 days post final dose

Secondary outcomes

  1. Number of subjects with adverse events (AEs)/serious AEs (SAEs), and change from baseline for vital signs, electrocardiograms (ECGs), and laboratory safety tests

    Safety and tolerability of different AZD6234 SC formulations

    Time frame: Through study duration, approximately 19 weeks

  2. Time of maximum observed plasma concentration (tmax)

    Pharmacokinetics (PK) of different AZD6234 SC formulations

    Time frame: Plasma sample collection from pre- dose to 30 days post final dose

  3. Terminal elimination half-life (t1/2)

    Pharmacokinetics (PK) of different AZD6234 SC formulations

    Time frame: Plasma sample collection from pre- dose to 30 days post final dose

  4. Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F)

    Pharmacokinetics (PK) of different AZD6234 SC formulations

    Time frame: Plasma sample collection from pre- dose to 30 days post final dose

  5. Volume of distribution based on the terminal phase calculated using AUC0-inf after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F)

    Pharmacokinetics (PK) of different AZD6234 SC formulations

    Time frame: Plasma sample collection from pre- dose to 30 days post final dose

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Sep 2026, 10 months.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 10 months is above that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Completion moved once since we started tracking on Sep 25, 2026: May 2027 → Sep 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2025
First posted
Oct 24, 2025
StartActual
Nov 11, 2025
Primary completionActual
Sep 16, 2026
CompletionActual
Sep 16, 2026was May 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Primary completion
Sep 17, 2026→Sep 16, 2026 (actual)
Oct 15, 2026
Study completion
May 21, 2027→Sep 16, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Completed
    Primary completion Sep 17, 2026→Sep 16, 2026 (now actual)
    Study completion May 21, 2027→Sep 16, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07220954
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Nov 11, 2025
Primary completion
Sep 16, 2026
Completion
Sep 16, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD6234

Start the discussion